The largest database of trusted experimental protocols

5 protocols using aeb071

1

Combinational Therapy Evaluation in Oncology

Check if the same lab product or an alternative is used in the 5 most similar protocols
The PARP inhibitor olaparib, partially provided from Novartis Institutes for Biomedical Research (NIBR, Cambridge, UK) and Astra-Zeneca (Oncology Bioscience, Cambridge, UK), was orally administered at a daily dose of 50 mg/kg or 100 mg/kg, five days a week, depending to the tolerance of tested combinations. Two cytotoxic agents were tested, both alkylating agents, i.e., dacarbazine (Deticene® or DTIC) (Medac, Lyon, France) and fotemustine (Muphoran®) (IRIS, Orly, France). Five different targeted therapies were used, the mTORC1 inhibitor everolimus (RAD001, Certican®) (Novartis, Basel, Switzerland), the pan-PKC inhibitor AEB071 (provided from Novartis), the MDM2 inhibitor CGM097 (provided from Novartis), the ATM inhibitor AZD0156 (provided from Astra-Zeneca), and the ATR inhibitor AZD6738 (provided from Astra-Zeneca). All treatment schedules are presented in the Table S11.
+ Open protocol
+ Expand
2

Investigating Targeted Cancer Therapies

Check if the same lab product or an alternative is used in the 5 most similar protocols
PIM447 and AEB071 were provided under material-transfer agreement (MTA) with Novartis Oncology. Ibrutinib was provided under MTA with Pharmacyclics. Silvestrol was a gift of Jerry Pelletier, McGill University. AZD1208 was purchased from Selleck Chemicals.
+ Open protocol
+ Expand
3

Sotrastaurin and BYL719 Dissolution

Check if the same lab product or an alternative is used in the 5 most similar protocols
AEB071 (Sotrastaurin) and BYL719 were supplied by Novartis (Switzerland) and dissolved in DMSO at 10mM concentration and stored aliquoted at −20 C.
+ Open protocol
+ Expand
4

Targeted Inhibitor Evaluation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All drugs used in this study (AEB071, CGM097, RAD001, MEK162, LEE011) were obtained from Novartis Institutes for Biomedical Research (NIBR, Cambridge, USA). AEB071, MEK162, RAD001, CGM097 and LEE011 are selective inhibitors of PKC, MEK1/2, mTORC1, MDM2 and CDK4/6 respectively. For in vivo administration, compounds were diluted in 20% propylene glycol + 50% solutol + 30% PBS. The control groups were treated with this solution (vehicle). Each compound was administrated 5 days a week at the dose indicated in each figure legend (see Supplementary Materials for further details).
For in vitro experiments, compound powders were dissolved in DMSO for a stock concentration of 10mM final, aliquoted and stored at −20°C. Further dilutions were made according to each experiment design.
+ Open protocol
+ Expand
5

Tregs Suppress T Cell Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Different subsets of Tregs were treated or not, washed three times, and added at ratio 1:3 (1.25 × 105 Tregs: 5 × 105 CD4+CD25 T cells) to CD4+CD25 T cells at final concentration 2 × 106/ml. The cells were co-cultured on anti-CD3 mAb (5 μg/ml) pre-coated 24-well plates for 48 hr. The PKC-θ inhibitor, AEB071, was provided by Novartis (Ridgefield, CT) and dissolved in DMSO. T cells were pretreated for 30 min with 10 μM at 37 °C and washed three times. Cytokine secretion was determined by ELISA as previously described20 (link), using Human IL-17 (R&D Systems Inc, Minneapolis, MN) and IFN-γ Cytosettm (Biosource; Camarillo, CA). The capacity of expanded Tregs to suppress target cell proliferation in vitro was assessed by using 5-carboxyfluorescein-diacetate-succinimide ester (CFSE) inhibition assay31 (link). Peripheral blood mononuclear cells (PBMCs) were purified, labeled with CFSE (InVitrogen), and stimulated with anti-CD3 mAb-coated beads (Dynal) in 96-well round-bottom plates with or without expanded cells (Treg:PBMC at ratios of 1:4-1:64). Assays were harvested on day 4. Cells were stained with anti-CD4 and/or −8 mAb and data acquired by LSRII. Data was analyzed using the proliferation platform in FlowJo (Treestar, Ashland, OR), and suppression determined from the Division Index.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!